IngredientsFull name: Active Hexose Correlated Compound (AHCC®). The name reflects the compound's origin as a mixture of biologically active hexose (six-carbon sugar) oligosaccharides correlated with downstream immune effects. It is a registered trademark of Amino Up Co., Ltd.
AHCC is a mixture of polysaccharides, amino acids, lipids, and minerals derived from cocultured mycelia of several species of Basidiomycete mushrooms. The primary and best-characterized source species is Lentinula edodes (also synonymously referred to in the literature as Lentinus edodes), commonly known as the shiitake mushroom. AHCC is a mushroom extract derived from several species of Basidiomycetes mushrooms, including Shiitake (Lentinus edodes) and Shimeji (Lyophyllum shimeji).
AHCC is a proprietary extract derived from the mycelia of shiitake (Lentinus edodes) mushrooms. It is rich in alpha-1,4-glucan oligosaccharides that are thought to enhance its biological effects. Critically, AHCC is derived not from the mushroom fruiting body (the familiar cap-and-stem structure) but specifically from the mycelia — the filamentous, root-like vegetative part of the fungus. While AHCC is derived from shiitake mycelia, it undergoes a unique patented manufacturing process that produces a distinct polysaccharide profile — specifically, low-molecular-weight alpha-glucans. Standard shiitake extracts are typically rich in beta-glucans with much higher molecular weights. The two are compositionally different products.
The supplemental forms, sold as capsules, tablets, and softgels, are used to support the immune system, as well as to prevent and treat cancer. AHCC is also available in liquid form; the liquid formulation was used in early Phase I safety studies. A freeze-dried preparation of AHCC (AHCC-FD) has been used in toxicological studies to further develop the body of evidence supporting the safety of this ingredient. All commercially distributed AHCC bulk powder originates from a single manufacturer: all AHCC bulk powder sold in the world is manufactured only at Amino Up Co., Ltd.'s facilities in Sapporo, Japan.
AHCC was developed in 1987 at the University of Tokyo Faculty of Pharmaceutical Sciences, along with other researchers, as a natural product for use in regulating high blood pressure. AHCC was developed by Amino Up Co., Ltd. and Toshihiko Okamoto (School of Pharmaceutical Sciences, University of Tokyo) in 1989. The precise year of first commercial launch is cited slightly differently across sources; AminoUp's leading supplement, AHCC, was launched in 1987, following an evaluation of more than 100 different mushroom species, and systematically tested for optimized manufacturing.
AHCC was initially developed as a natural product for regulating high blood pressure. However, AHCC is now primarily known for its immunostimulant potential in protecting against viruses, cancers, and infections. AHCC is being researched in the United States, China, Korea, Japan, and Thailand. Today, AHCC is used as a dietary supplement in over 40 countries and has been the subject of more than 30 human clinical studies and over 100 preclinical (laboratory and animal) studies.
AHCC itself has no historical or traditional use — it is an entirely modern, proprietary ingredient developed in a laboratory setting in the late 1980s. Its traditional context derives entirely from the long history of the Lentinula edodes mushroom from which it is manufactured.
Shiitake mushrooms have been used medicinally in East Asia for more than 2,000 years. Because of their very good culinary properties, they are popular mushrooms worldwide. The medicinal properties of L. edodes have been studied since the Ming Dynasty (1369–1644). The elders of the Japanese Empire considered shiitake as the "elixir of life," increasing vigor and energy.
AHCC is produced from the mycelia of shiitake mushrooms, or Lentinula edodes. These mushrooms are native to East Asia and have been popular in the cuisines of many Eastern countries for hundreds of years. For centuries, shiitake mushrooms have been credited in East Asia for their uses in traditional medicine, with many historic writings pointing to their health-boosting effects. These mushrooms are abundant in the mountainous regions of East Asia and have been a part of East Asian cuisine for a very long time. However, it was not until the 18th century that shiitake mushrooms were successfully cultivated.
While not part of ancient herbal traditions, AHCC builds upon centuries of medicinal mushroom use in Asian cultures, where mushrooms such as shiitake, maitake, and reishi have long been valued for promoting longevity, vitality, and resilience against disease. The shiitake's bioactive compound lentinan, a purified β-1,3-D-glucan, was the subject of earlier pharmacological interest in Japan and forms a part of the broader context from which interest in AHCC grew; as an example, researchers use the medicinal and culinary mushroom Lentinula edodes, shiitake, and some of its isolated compounds, mainly lentinan and eritadenine. In the history of mankind, plants and fungi were for a long time the only available means for the treatment of health problems, used in the form of whole plants and mushrooms or extracts prepared therefrom.
The production of AHCC involves a multi-step, proprietary fermentation and extraction process that distinguishes it from conventional shiitake or other mushroom preparations. AHCC is a standardized extract of cultured shiitake or Lentinula edodes mycelia which contains a mixture of nutrients including oligosaccharides, amino acids, and minerals obtained through the liquid culture process of shiitake mycelia. It is produced by Amino Up Co., Ltd. (Sapporo, Japan). The shiitake mycelia used for AHCC are cultured in a liquid medium where the mycelia proliferate and form globular fungal bodies but not fruiting bodies. AHCC is produced through the unique manufacturing process of culturing the mycelia followed by separation, sterilization, and freeze-drying. The most abundant component of AHCC is oligosaccharides, which comprise about 74% of the dry weight of AHCC.
Derived from the cells of shiitake mushroom mycelia and slowly cultured with a unique mix of nutrients for nearly two months, AHCC consists of a mix of mostly polysaccharides, large sugar polymers. These polysaccharides, researchers at AminoUp reported in the European Journal of Nutrition, stimulate specific receptors located on human immune cells in the gut that recognize foreign pathogens such as viruses and bacteria.
The mycelia are grown in a rice bran-based liquid culture medium. During this process, the mycelia are grown in a liquid culture medium based on rice bran. During the fermentation process, the mycelia convert components of the medium into other nutrients. This process is long, taking about two months, but the final AHCC (including partially acetylated alpha-glucans) possesses unique properties. After culturing, mycelia of shiitake mushrooms are cultured for 30 to 40 days from the preculture process to the large-size tank culture process. Then the culture liquid is concentrated, sterilized, and freeze-dried to be AHCC.
AHCC is a proprietary nutritional supplement derived from the cocultured mycelia of shiitake mushrooms within the Basidiomycetes family, consisting primarily of low-molecular-weight alpha-glucans (approximately 20% α-1,4-glucans and acetylated forms) alongside polysaccharides, amino acids, lipids, and minerals, with an average molecular weight of about 5,000 daltons.
The alpha-glucan fraction is considered the principal active component. The main component of AHCC is acetylated α-glucan, which is relatively much easier to absorb than β-glucan (the main component of mushroom products). α-1,4-Glucan has a much lower molecular weight (5,000 Daltons) than β-glucan (10,000–500,000 Daltons). This low molecular weight is considered significant for bioavailability.
Nearly 20% of this fraction is composed of the α-1,4-glucans and their acetylated forms with an average molecular weight of 5,000. Consequently, these oligosaccharides may account for the biological activities associated with AHCC.
In addition to the defining alpha-glucan fraction, AHCC is a mushroom extract derived from several species of Basidiomycetes mushrooms, including Shiitake (Lentinus edodes) and Shimeji (Lyophyllum shimeji). It contains a mixture of amino acids, minerals, polysaccharides, and lipids enriched in α-1,4-linked glucans.
The manufacturer of AHCC, Amino Up Co., Ltd., states that the culturing process utilized in its manufacture favors the release of small bioactive molecules that act as nontoxic agonists for toll-like receptors (TLRs), specifically TLR-4, initiating a systemic anti-inflammatory response. AHCC is believed to bind to TLR-2 and TLR-4, and act as an immune modulator, as immune cells such as CD4+ and CD8+ T cells and natural killer (NK) cells will produce cytokines by either cytokine stimulation by dendritic cells or ligand binding to TLRs.
α-1,4-Glucans exert immunostimulatory effects and induce immune receptors, such as toll-like receptors (TLRs), which are expressed on many cell types. Previous studies have shown that AHCC has immunostimulatory effects on intestinal epithelial cells and monocytes via the activation of TLR2 and TLR4 signaling pathways. Furthermore, AHCC exerts immunostimulatory effects on intestinal epithelial cells and monocytes involving TLR4/MyD88 and NFκB/MAPK signal transduction pathways.
AHCC is an immunostimulatory agent that has effects on monocytes, natural killer (NK) cells, T cells, and natural killer T (NKT) cells.
Clinical research and studies have shed light on AHCC's mechanism of action. It is believed that AHCC works by increasing the number of dendritic cells and enhancing natural killer (NK) cell and T cell activity in both the innate and adaptive immune responses. NK cells and T cells play a vital role in identifying and eliminating harmful cells, such as viruses and cancer cells.
The effects of AHCC on T cells could be mediated by affecting innate immune cells since oligosaccharides including α-glucans and β-glucans are known to stimulate innate immune cells such as monocytes, macrophages, and dendritic cells that can modulate the activation and differentiation of downstream adaptive immune responses.
Treatment with AHCC enhanced both antigen-specific activation and proliferation of CD4+ and CD8+ T cells, increased the number of tumor antigen-specific CD8+ T cells, and more importantly, increased the frequency of tumor antigen-specific IFN-Îł producing CD8+ T cells.
AHCC can induce high levels of IL-1β production from human monocytes. Furthermore, AHCC-treated monocytes increased the production of IL-17 and IFN-γ from autologous CD4+ T cells, which was blocked by adding IL-1 receptor antagonist. This IL-1β-mediated pathway provides a mechanistic link between AHCC's interaction with innate monocytes and the downstream activation of T helper 17 (Th17) and Th1 adaptive immune responses.
Studies have shown that AHCC promotes the activation of T helper 1 (Th1) and T helper 17 (Th17) cells and improves the function of dendritic cells (DCs).
Proposed mechanisms include orchestrating immune responses and maintaining immune homeostasis in part by priming TLR-2 and TLR-4 (toll-like receptor) gates at the intestinal epithelium. AHCC is a cultured mushroom extract promoted for immune support. Available data suggest that AHCC supplementation affects immune cell populations and immune outcomes, including natural killer cell response to infection. The mechanism by which AHCC exerts its effects is not well understood. Work has aimed to characterize the immunomodulatory activity of AHCC in the gut and to study the effects of AHCC on toll-like receptor (TLR) signaling in intestinal epithelial cells.
AHCC inhibited constitutive signal transducer and activator of transcription 3 (STAT3) phosphorylation in ovarian cancer cell lines. Treatment with pervanadate, a protein tyrosine phosphatase inhibitor, reversed AHCC-induced STAT3 suppression. AHCC treatment induced the expression of SHP-1, a protein tyrosine phosphatase, and suppressed the expression of cyclin D1, Bcl-2, Mcl-1, survivin, and VEGF, which are STAT3-regulated gene products. These findings are from in vitro studies in cancer cell lines and have not been replicated in clinical trials.
In patients with hepatocellular carcinoma and cirrhosis, beneficial effects on liver function are thought to be via regulation of nitric oxide production.
Evidence level: Preliminary; small, short-duration randomized controlled trials (RCTs) in humans.
A Phase I safety and pharmacodynamic study enrolled healthy volunteers. The number of circulating dendritic cells (both DC1 and DC2 cells), natural killer (NK) cells, and CD4+/CD8+ T lymphocytes were measured by flow cytometry. Volunteers supplemented with AHCC had significantly greater numbers of total dendritic cells than at baseline, and DC1 and DC2 cells were significantly increased after 4 weeks compared with the control. The allo-stimulatory activity of DC1s was also increased after intake compared with control as measured by the mixed lymphocyte reaction (MLR).
A randomized, double-blind, placebo-controlled trial evaluated AHCC's effect on responses to seasonal influenza vaccination. A total of 29 subjects were enrolled: 14 were supplemented with AHCC (total of 3,000 mg/day) and 15 were given a placebo on the day of vaccination throughout two weeks post-vaccination. Blood was drawn at immunization and two weeks later for phenotypic analysis of lymphocytes using flow cytometry. The fold increases in percentages of T cells, CD8+ T (cytotoxic) cells, CD56+ (NK) cells — but not CD4/CD8 ratios — were significantly higher than at vaccination for AHCC-supplemented subjects. Although AHCC supplementation did not alter NK cell percentages post-vaccination, CD56 bright cytotoxic NK cells were higher in the AHCC than the placebo group. AHCC supplementation had a more dramatic effect on immune cell phenotypes after vaccination of subjects over 60 years of age.
A separate RCT in 29 healthy adults found that AHCC supplementation improved some lymphocyte percentages and influenza B antibody titers over the control. Changes in lymphocyte subpopulations revealed that AHCC supplementation increases CD8 T cells and NK-T cells following vaccination compared with controls.
A study in 34 healthy volunteers examined AHCC's effect during winter seasonal immune decline. The research involved 34 healthy volunteers who took either 1.0 g/day of AHCC or a placebo for 4 weeks during early winter. Normally, there is a seasonal decline in immune response during this time, which was seen in the placebo arm of the trial. In the group taking AHCC, they preserved their natural killer (NK) cell counts despite seasonal changes. Overall, the immune competence score stayed stable in the AHCC group but dropped in the placebo group during winter.
Limitations: All human immune-function studies in healthy adults are small (≤34 subjects), short in duration, and many are industry-affiliated. Surrogate endpoints (cell counts, antibody titers) have not been translated into clinical outcomes such as reduced infection incidence.
Evidence level: Preliminary; several small prospective and observational human studies with positive signals, but no large independent RCTs to date.
A study investigated whether AHCC could prolong survival and improve the prognosis of patients with advanced liver cancer. A prospective cohort study was performed with 44 patients with histologically confirmed liver cancer, all of whom underwent supportive care. Survival time, quality of life, clinical and immunological parameters related to liver function, cellular immunity, and patient status were determined. Of the 44 patients, 34 and 10 received AHCC and placebo (control) orally, respectively. Patients in the AHCC-treated group had a significantly prolonged survival when compared to the control group. Quality of life in terms of mental stability, general physical health status, and ability to have normal activities were significantly improved after 3 months of AHCC treatment.
Two small studies suggest that AHCC may improve outcomes among patients with liver cancer. Larger, randomized controlled studies, however, are needed to confirm these findings.
A 2022 prospective clinical trial at Hokkaido University examined post-surgical HCC patients. A prospective clinical trial at Hokkaido University enrolled 29 HCC patients receiving AHCC after curative liver resection. The 2-year recurrence-free survival rate was 48–55.2% — better than historical benchmarks. Inflammation-based prognostic scores (NLR, PNI, SII) remained within favorable ranges throughout the follow-up period.
Studies examining liver enzyme function have also been conducted. Participants with alcohol-induced mildly elevated liver enzyme levels were randomly allocated to placebo, 1 g AHCC, or 3 g AHCC groups and took the supplement for 12 weeks. AHCC supplementation for 12 weeks may improve the levels of liver enzymes and circulating pro-inflammatory and anti-inflammatory cytokines in patients with alcohol-induced liver enzyme elevation.
Limitations: The liver cancer studies are small, uncontrolled, or non-randomized. The prospective cohort design (rather than double-blind RCT) of the main survival study and the imbalance in group sizes (34 vs. 10) limit conclusions. Potential benefits with this compound in patients with cancer have been reported in a few uncontrolled or nonrandomized studies.
Evidence level: Preliminary; several small human studies suggest reduced adverse effects, but data are largely retrospective or pilot in nature.
A retrospective study examined the effect of AHCC in women receiving adjuvant chemotherapy for breast cancer. It was found that compared with the control group, the AHCC group had significantly fewer neutrophil-related events (odds ratio: 0.30; p = 0.016), significantly lower use of granulocyte colony-stimulating factor, and a higher (although not significant) rate of adverse events associated with Îł-glutamyl transpeptidase, a liver enzyme. AHCC has the potential to reduce the severity of neutropenia induced by breast cancer chemotherapy and the need to use granulocyte-CSF during chemotherapy as a remedial therapy. Overall data suggest that AHCC may reduce the toxicity of chemotherapy and may then allow for intensification of the chemotherapy dosage. A prospective trial is needed to study the effects of AHCC related to adverse events associated with Îł-GTP.
A study in patients with epithelial ovarian cancer or peritoneal cancer receiving platinum-based chemotherapy found that in a randomized, double-blind, placebo-controlled trial, 28 epithelial ovarian cancer patients receiving platinum-based chemotherapy received either AHCC 3 g/day or placebo across 6 chemotherapy cycles. CD8+ T cell levels were significantly higher in the AHCC group at the completion of the sixth cycle (p=0.03). Nausea and vomiting were significantly reduced in the AHCC group.
In-human studies suggest that AHCC is well-tolerated and may reduce the incidence of adverse effects among patients receiving chemotherapy.
Limitations: Most chemotherapy support studies are small, retrospective, or lack rigorous placebo controls. The mechanistic pathway through which AHCC might reduce neutropenia is not fully established in humans.
Evidence level: Moderate preliminary; one small randomized double-blind placebo-controlled trial with statistically significant results, requiring replication in a larger trial.
The most rigorously designed human clinical trial of AHCC to date focused on HPV. The objective was to determine the efficacy, safety, and durability of AHCC supplementation for 6 months to support the host immune system to clear high-risk HPV infections. This was a randomized, double-blind, placebo-controlled study in 50 women over 30 years of age with confirmed persistent high-risk HPV infections for greater than 2 years. Patients were randomized to placebo once daily for 12 months (N=25) or AHCC 3-g supplementation by mouth once daily on an empty stomach for 6 months followed by 6 months of placebo (N=25).
Fifty women with high-risk HPV were enrolled, and 41 completed the study. Fourteen (63.6%) of the 22 patients in the AHCC supplementation arm were HPV RNA/HPV DNA negative after 6 months, with 64.3% (9/14) achieving a durable response defined as being HPV RNA/HPV DNA negative 6 months off supplementation. On the placebo arm, two (10.5%) of 19 patients were HPV negative at 12 months.
Limitations: The sample size was small (50 enrolled, 41 completed). The study was performed at a single institution. While the between-group difference was large and statistically striking, independent replication in a larger, multi-center RCT has not yet been published. The study was investigator-initiated, and industry funding relationships should be considered.
Evidence level: Supportive preclinical (animal) data; limited but positive human immunological data; no clinical endpoint trials in human influenza infection.
In mouse models, young C57BL/6 mice were supplemented with 1 g AHCC/(kg body weight Ă— d) for 1 week prior to and throughout infection with influenza A (H1N1, PR8). Supplementation increased survival, decreased the severity of infection, and shortened recovery time following intranasal infection with flu. AHCC increased NK activity in lungs at day 1 (P < 0.05) and day 4 (P < 0.01) and in the spleen at day 2 postinfection (P < 0.01).
Another mouse study demonstrated dose-dependent effects: male C57BL/6 mice were supplemented with AHCC at daily doses of 0.05, 0.1, 0.5, and 1 g/kg and infected intranasally with influenza A virus (H1N1, PR8). Supplemented mice demonstrated a dose-dependent increase in survival and reduction in the loss of body weight.
The survival benefit by AHCC supplementation was observed in mice infected with avian (bird) influenza virus H5N1, which could infect humans and poultry, although its mechanism is yet to be demonstrated. The mortality rate of H5N1 avian influenza is much higher than that of past influenza pandemics, reaching up to 60%. The available data support the implication of NK cells in controlling influenza virus via promoting the number and function of NK cells, raising the possible consideration of exploring the clinical utility of AHCC for influenza viral infections, including avian influenza infection, in humans.
AHCC enhanced natural killer cell activity to induce endogenous IL-12 in mice, improved murine response to influenza infection, increased resistance to West Nile virus by improving T-cell response, and increased resistance to bacterial infection, likely via increasing inflammatory cytokine and chemokine expression as well as lymphocytes.
Limitations: No randomized controlled clinical trials have been conducted measuring infection incidence or severity as a clinical outcome in humans with influenza. Evidence in humans is limited to immunological biomarkers following vaccination. Animal and human data should not be conflated.
Evidence level: Predominantly preclinical (in vitro and animal); limited clinical data.
In the area of ovarian cancer, in vitro data showed that ovarian cancer cell viability was significantly reduced through treatment with AHCC compared to that in the control. These are cell-line results and do not represent clinical evidence of efficacy.
In acute myeloid leukemia (AML), preclinical work found that AHCC increased Caspase-3-dependent apoptosis of AML cells in vitro and in mice, and induced Fas and Caspase-8, members of the extrinsic apoptotic pathway. AHCC has improved the prognosis and quality of life of patients with liver, lung, head, and neck cancers in observational and small prospective studies, though the strength of evidence for cancer types other than HCC is weaker.
In a mouse model of melanoma, AHCC significantly delayed tumor development after B16-F0 melanoma inoculation. This phenomenon was accompanied by an increase in the number of NK cells, tumor antigen-specific CD8+ T cells producing IFN-Îł, and gamma delta T cells. These are animal findings only.
An ongoing clinical trial (NCT07118735) is evaluating AHCC as an immune modulator in cancer patients treated with immunotherapy, reflecting continued research interest in this area.
Evidence level: Preliminary; a small randomized trial with positive findings.
To investigate the effects of AHCC supplementation in patients with alcohol-induced mildly elevated liver enzyme levels, participants were randomly allocated to the placebo, 1 g AHCC, or 3 g AHCC group and took the supplement for 12 weeks. AHCC supplementation for 12 weeks may improve the levels of liver enzymes and circulating pro-inflammatory and anti-inflammatory cytokines in patients with alcohol-induced mildly elevated liver enzyme levels.
In patients with hepatocellular carcinoma and cirrhosis, beneficial effects on liver function are thought to be via regulation of nitric oxide production.
The following dosages are reported directly from published clinical research and should not be interpreted as general recommendations:
Multiple preclinical and clinical studies have established a broadly favorable safety profile for AHCC. AHCC is associated with immunostimulatory effects. AHCC-FD was not mutagenic to Salmonella typhimurium and did not exhibit clastogenicity in a mouse micronucleus assay. In a 90-day study, Sprague-Dawley rats were administered 1,000, 3,000, or 6,000 mg/kg body weight/day by gavage. No changes attributable to AHCC-FD treatment were observed in overall condition, body weight, food consumption, ophthalmology findings, hematology and clinical chemistry parameters, and absolute and relative organ weights. Changes in urinary pH values observed in high-dose animals and mid-dose females were considered physiological rather than adverse effects given the acidic nature of AHCC-FD. Urinary protein was also increased in the same dose groups. As this finding was associated with decreased urinary pH and no evidence of kidney dysfunction was observed, it was considered of no toxicological significance. Histopathological changes related to AHCC-FD administration were observed in the limiting ridge of the stomach and in the liver of the high-dose group. The NOAEL was considered to be 3,000 mg/kg body weight/day.
The manufacturer also reports toxicity thresholds from internal testing: Acute oral toxicity test LD50 > 12,500 mg/kg; subchronic oral toxicity study NOAEL = 3,000 mg/kg/day; reverse mutation test (Ames test): Negative; micronucleus test: Negative. No serious adverse effect has been reported since its launch in 1987.
AHCC is non-toxic, with high doses eliciting only mild adverse events. A Phase I trial documented mild GI complaints, including nausea, diarrhea, and bloating. Some patients reported headache, fatigue, and foot cramps with the liquid form of AHCC. The Phase I study enrolled 26 healthy male or female volunteers between 18 and 61 years of age. Two subjects (7%) dropped out because of nausea and intolerance of the liquid.
The most clinically significant safety concern regarding AHCC relates to its ability to modulate cytochrome P450 enzymes and aromatase, with potential implications for patients on certain cancer medications.
CYP2D6 induction: AHCC has been shown to induce CYP450 2D6 in an ex vivo model and may render substrate drugs such as doxorubicin and ondansetron less effective. The clinical significance of these interactions has yet to be determined. AHCC induces CYP2D6, which may decrease the activity of substrate drugs such as doxorubicin or ondansetron. Clinical significance is not known.
Aromatase inhibitors: In the ZR-75 model (COMT wild-type), there was no difference in activity with the letrozole + AHCC combination compared with letrozole alone. However, in the MCF-7 model (COMT variant), AHCC + letrozole resulted in a decrease in activity compared with letrozole (P < 0.01). Immunoassay data suggested that AHCC is a potential inducer of aromatase activity. In both tumor models, there was cytotoxicity observed with AHCC compared with untreated (P < 0.02). AHCC did not change the activity of tamoxifen. AHCC may have some interaction with letrozole in patients with COMT variant genotype.
Data suggest that AHCC is safe to administer with most other chemotherapy agents not metabolized by CYP2D6. Data also show that AHCC potentially induces aromatase enzyme activity when given alone. Concomitant use with aromatase inhibitors is not recommended until further studies have been conducted.
Aromatase inhibitors: AHCC induces aromatase and may reduce activity of aromatase inhibitor drugs such as letrozole. Aromatase inhibitors are medications that stop an enzyme called aromatase from changing hormones into estrogen. Examples of aromatase inhibitors include letrozole (Femara®) and anastrozole (Arimidex).
AHCC induces the CYP2D6 enzyme, which could affect the metabolism of roughly 25% of prescription drugs. The clinical scope of this interaction in humans has not been fully characterized, and no large-scale clinical pharmacokinetic interaction study has been published.
Physicians should be aware of the growing interest by patients in nutritional products such as active hexose correlated compound for preventing and treating cancer and their potential for interactions with some prescription drugs.
The body of published AHCC research is extensive relative to most dietary supplements, with peer-reviewed preclinical and clinical publications spanning more than three decades. However, several overarching limitations apply across the research base:
Health conditions that AHCC may help support.
AHCC (Active Hexose Correlated Compound), a standardized alpha-glucan extract from cultured Lentinula edodes mycelia, has demonstrated immunomodulatory activity in clinical studies including increased NK-cell activity. Studies show it reduces infection susceptibility and has shown evidence of reducing serious respiratory infections including pneumonia in immunocompromised patients. Preclinical studies show improved survival in H1N1 influenza pneumonia.
AHCC is a standardized mushroom extract (Lentinula edodes mycelia) primarily composed of α-glucans, with documented immunomodulatory properties in both animal and clinical studies. Clinical evidence shows AHCC decreases infection risk, ameliorates symptoms of existing infections, and enhances T-lymphocyte and NK cell counts—all relevant to post-illness immune restoration.
AHCC (Active Hexose Correlated Compound), a shiitake mushroom extract, has clinical evidence for modulating immune function to support resolution of persistent viral infections. A Phase II RCT at UT Health demonstrated AHCC 3 g/day supported host immune clearance of persistent HPV infections. AHCC has been shown to decrease infection risk and ameliorate symptoms of existing viral and bacterial infections in clinical studies.
AHCC (Active Hexose Correlated Compound) is a standardized shiitake mycelia extract primarily composed of α-glucans. Human pilot studies and RCTs show it enhances NK cell, T cell, and dendritic cell activity against viral pathogens. Clinical studies specifically demonstrate support for clearing persistent HPV viral infections.
Body systems that AHCC may help support.
Go back